Guideline Summary for Management of Acute Kidney Injury After Nephrectomy

Immediate Management Actions

Discontinue all nephrotoxic medications immediately, initiate isotonic crystalloid therapy (0.9 % saline or balanced solution) aiming for a modest positive fluid balance of 1–2 L by the end of the operative day, and institute close renal function monitoring to prevent further injury【1】【2】【3】.

Stop any nephrotoxic drug when it is suspected to contribute to AKI, when a less nephrotoxic alternative exists, or when the drug is non‑essential【1】【2】.
Do not start new nephrotoxic agents in patients with known AKI risk factors (e.g., advanced age, prior AKI, chronic kidney disease, diabetes, proteinuria, hypertension) unless absolutely required【1】【4】.
Specifically avoid non‑steroidal anti‑inflammatory drugs and aminoglycosides unless no therapeutic alternatives are available【5】.
When nephrotoxic therapy is unavoidable, minimize its dose and duration and perform regular renal function checks【3】【6】.

Hold ACE inhibitors and ARBs throughout the acute AKI phase; plan re‑initiation only after serum creatinine stabilizes and volume status is optimized【1】【2】【7】.
Recognize that abrupt discontinuation can lower filtration fraction and may transiently worsen AKI【1】【3】.
Failure to restart these agents after surgery is associated with increased 30‑day mortality, likely due to hypertensive rebound and cardiac decompensation【1】【3】【7】.
Re‑introduce ACEi/ARB when glomerular filtration rate is stable, volume status is euvolemic, and the risk of hypotension is low【1】【7】.
Weigh the renal‑cardiac risk‑benefit for each patient before restarting【3】【8】.

Use isotonic crystalloids (normal saline or balanced solutions) to achieve a mildly positive balance of 1–2 L by the end of the postoperative period【9】.
Avoid “zero‑balance” fluid strategies, which have been shown to increase AKI incidence compared with modestly liberal regimens【9】.
Preferred volume expanders are isotonic sodium chloride or sodium bicarbonate solutions【10】.
Do not employ hydroxyethyl starch for volume replacement pending new evidence【9】.
Routine use of albumin or synthetic colloids is not recommended【9】.
Monitor closely for fluid overload, especially in individuals with underlying heart or lung disease who have reduced fluid tolerance【9】.

Perform therapeutic drug‑level monitoring for nephrotoxic medications whenever assays are available to guide dose adjustments【1】【2】.

Initiate RRT emergently only for life‑threatening complications: refractory hyper‑kalemia, severe volume overload unresponsive to diuretics, intractable metabolic acidosis, or uremic manifestations (e.g., encephalopathy, pericarditis, pleuritis)【11】.
Do not rely solely on isolated BUN or creatinine thresholds; clinical context and trend data must inform the decision【11】.
For hemodynamically unstable patients, preferentially use continuous RRT rather than intermittent modalities【11】.
Target a weekly Kt/V of 3.9 for intermittent RRT regimens【11】.
Aim for an effluent flow rate of 20–25 mL kg⁻¹ h⁻¹ during continuous RRT【11】.

AKI modifies both renal and hepatic drug metabolism through alterations in cytochrome P450 activity, protein binding, and volume of distribution【6】【7】【4】.
Direct extrapolation of chronic kidney disease dosing recommendations to acute settings is unreliable; dosing should reflect the acute nature of the injury【6】【7】.
Inter‑organ crosstalk between the kidney and liver significantly influences drug clearance and should be considered when adjusting regimens【6】【4】.
Whenever possible, apply evidence‑based dosing guidelines specific to AKI to optimize therapeutic efficacy and safety【3】【6】.

Do not withhold essential nephrotoxic agents (including intravenous contrast) in life‑threatening situations solely because of AKI concerns【12】.
Low‑dose dopamine, fenoldopam, and atrial natriuretic peptide have no proven benefit for AKI prevention or treatment and should be avoided【5】.
N‑acetylcysteine is not effective for preventing postoperative AKI and should not be used for this purpose【5】【10】.
Pre‑operative fluid restriction increases AKI risk and should be avoided【10】.